Join us for an informative discussion on one of the biggest reforms to the Canadian Food and Drugs Act in more than 50 years. Our expert panel will set out the material changes to the legislation and also shine a light on the industry perspective. Learn about the substantive changes to the characterization of certain regulated products, the application of broader ministerial powers to require disclosure of confidential information and other increased surveillance and risk-mitigation requirements. Get the tools that you need to better understand the implications of the reformed regulatory environment and advise your clients of how to best market therapeutic products in Canada, while ensuring compliance with the law and improving patient safety.

SPEAKERS

David K. Edwards, Senior Counsel, Health Canada Legal Services Unit
Declan Hamill, Chief of Staff and Vice-President, Legal Affairs, Canada's Research-Based Pharmaceutical Companies

PROGRAM CHAIR

Rajeev Sharma, Torkin Manes LLP
Ratika Gandhi, McMillan LLP